면역치료제 시장 규모, 점유율, 동향, 산업 분석 보고서 : 유형별, 용도별, 투여 경로별, 최종사용자별, 지역별 - 시장 예측(2025-2034년)

The global immunotherapy drugs market size is expected to reach USD 1,152.03 billion by 2034, according to a new study by Polaris Market Research. The report "Immunotherapy Drugs Market Size, Share, Trends, Industry Analysis Report: By Type (Antibody Drugs, Inhibitor Drugs, Interferons and Interleukins, Vaccines, and Others), Application, Route of Administration, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025 - 2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The immunotherapy drugs market involves the development, production, and sale of medications that use the body's immune system to treat diseases, particularly cancer, by targeting specific cells or pathways. The rising adoption of targeted therapy over traditional treatment methods is significantly driving the immunotherapy drugs market growth. Targeted therapies, such as monoclonal antibodies, are designed to specifically attack cancer cells or pathogens, which minimizes damage to healthy cells and reduces side effects commonly associated with conventional treatments such as chemotherapy. This shift towards more precise and effective treatments aligns with the increasing demand for personalized medicine, which tailors therapies to individual patient profiles based on genetic and disease characteristics. As a result, the immunotherapy drugs market demand is projected to grow over the forecast period.

The approval of new immunotherapy drugs and the expansion of their applications are further propelling market growth. For instance, in April 2024, AstraZeneca and Daiichi Sankyo's Enhertu were approved by the FDA as the first tumor-agnostic HER2-directed therapy for previously treated metastatic HER2-positive solid tumors, exemplifying the trend toward targeted immunotherapy solutions.

These advancements enhance treatment efficacy and also contribute to a broader acceptance of immunotherapy as a standard care option in oncology and other therapeutic areas. The growing prevalence of chronic diseases, including various cancers, is expected to increase the demand for these innovative therapies further, solidifying the immunotherapy drugs market expansion.

In recent years, increasing awareness and earlier detection of diseases, supported by healthcare organizations and advocacy groups, have significantly enhanced the immunotherapy drugs market by encouraging timely treatment. This proactive approach allows for better outcomes with immunotherapies. Further, advancements in biotechnology driven by research collaborations and substantial investments in R&D are fostering innovation in immunotherapy solutions. Together, these are expanding treatment options and improving patient care, thereby propelling market growth.

Immunotherapy Drugs Market Report Highlights

The antibody drugs segment dominated the immunotherapy drugs market due to their proven efficacy in treating cancers and autoimmune diseases with targeted precision.

The cancer segment held the largest immunotherapy drugs market share and is expected to remain dominant due to high unmet medical needs and the promising results of new therapies.

North America region held the largest revenue share of the market in 2024 due to high cancer prevalence, a robust healthcare system, significant investments in biotechnology, and rapid adoption of new therapies.

The immunotherapy drugs market in Asia Pacific is expected to grow fastest due to advancements in healthcare infrastructure, high disease incidence, and a strong pipeline of clinical trials and research.

The global key market players include Abbvie Inc.; Amgen Inc.; AstraZeneca; Bristol-Myers Squibb Company; F. Hoffman-La Roche Ltd.; Gilead Sciences, Inc.; GSK PLC; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Sanofi; and others.

Polaris Market Research has segmented the immunotherapy drugs market report based on type, application, route of administration, end user, and region:

By Type Outlook

§ Antibody Drugs

§ Inhibitor Drugs

§ Interferons and Interleukins

§ Vaccines

§ Others

By Application Outlook

§ Cancer

§ Autoimmune and Inflammatory Diseases

§ Hematology

§ Osteology

§ Neurology

§ Others

By Route of Administration Outlook

§ Intravenous

§ Subcutaneous

§ Oral

§ Others

By End User Outlook

§ Hospitals

§ Long-Term Care Facilities

§ Others

By Regional Outlook

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Immunotherapy Drugs Market Insights

• 4.1. Immunotherapy Drugs Market - Market Snapshot
• 4.2. Immunotherapy Drugs Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing Advancements in Immunotherapy Research & Development Activities
    • 4.2.1.2. Combination Therapies in Immunotherapy Drives Market Growth
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Regulatory Hurdles and Approval Delays
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Immunotherapy Drugs Market Application Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Immunotherapy Drugs Market, by Type

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
• 5.3. Antibody Drugs
  • 5.3.1. Global Immunotherapy Drugs Market, by Antibody Drugs, by Region, 2020-2034 (USD Billion)
• 5.4. Inhibitor Drugs
  • 5.4.1. Global Immunotherapy Drugs Market, by Inhibitor Drugs, by Region, 2020-2034 (USD Billion)
• 5.5. Interferons and Interleukins
  • 5.5.1. Global Immunotherapy Drugs Market, by Interferons and Interleukins, by Region, 2020-2034 (USD Billion)
• 5.6. Vaccines
  • 5.6.1. Global Immunotherapy Drugs Market, by Vaccines, by Region, 2020-2034 (USD Billion)
• 5.7. Other
  • 5.7.1. Global Immunotherapy Drugs Market, by Other, by Region, 2020-2034 (USD Billion)

6. Global Immunotherapy Drugs Market, by Application

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
• 6.3. Cancer
  • 6.3.1. Global Immunotherapy Drugs Market, by Cancer, by Region, 2020-2034 (USD Billion)
• 6.4. Autoimmune and Inflammatory Diseases
  • 6.4.1. Global Immunotherapy Drugs Market, by Autoimmune and Inflammatory Diseases, by Region, 2020-2034 (USD Billion)
• 6.5. Hematology
  • 6.5.1. Global Immunotherapy Drugs Market, by Hematology, by Region, 2020-2034 (USD Billion)
• 6.6. Osteology
  • 6.6.1. Global Immunotherapy Drugs Market, by Osteology, by Region, 2020-2034 (USD Billion)
• 6.7. Neurology
  • 6.7.1. Global Immunotherapy Drugs Market, by Neurology, by Region, 2020-2034 (USD Billion)
• 6.8. Other
  • 6.8.1. Global Immunotherapy Drugs Market, by Other, by Region, 2020-2034 (USD Billion)

7. Global Immunotherapy Drugs Market, by Route of Administration

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• 7.3. Intravenous
  • 7.3.1. Global Immunotherapy Drugs Market, by Intravenous, by Region, 2020-2034 (USD Billion)
• 7.4. Subcutaneous
  • 7.4.1. Global Immunotherapy Drugs Market, by Subcutaneous, by Region, 2020-2034 (USD Billion)
• 7.5. Oral
  • 7.5.1. Global Immunotherapy Drugs Market, by Oral, by Region, 2020-2034 (USD Billion)
• 7.6. Other
  • 7.6.1. Global Immunotherapy Drugs Market, by Other, by Region, 2020-2034 (USD Billion)

8. Global Immunotherapy Drugs Market, by End-User

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
• 8.3. Hospitals
  • 8.3.1. Global Immunotherapy Drugs Market, by Hospitals, by Region, 2020-2034 (USD Billion)
• 8.4. Long-Term Care Facilities
  • 8.4.1. Global Immunotherapy Drugs Market, by Long-Term Care Facilities, by Region, 2020-2034 (USD Billion)
• 8.5. Other
  • 8.5.1. Global Immunotherapy Drugs Market, by Other, by Region, 2020-2034 (USD Billion)

9. Global Immunotherapy Drugs Market, by Geography

• 9.1. Key Findings
• 9.2. Introduction
  • 9.2.1. Immunotherapy Drugs Market Assessment, By Geography, 2020-2034 (USD Billion)
• 9.3. Immunotherapy Drugs Market - North America
  • 9.3.1. North America: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
  • 9.3.2. North America: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • 9.3.3. North America: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
  • 9.3.4. North America: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.3.5. Immunotherapy Drugs Market - U.S.
    • 9.3.5.1. U.S.: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.3.5.2. U.S.: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.3.5.3. U.S.: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.3.5.4. U.S.: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.3.6. Immunotherapy Drugs Market - Canada
    • 9.3.6.1. Canada: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.3.6.2. Canada: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.3.6.3. Canada: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.3.6.4. Canada: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
• 9.4. Immunotherapy Drugs Market - Europe
  • 9.4.1. Europe: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
  • 9.4.2. Europe: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • 9.4.3. Europe: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
  • 9.4.4. Europe: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.4.5. Immunotherapy Drugs Market - UK
    • 9.4.5.1. UK: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.5.2. UK: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.4.5.3. UK: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.4.5.4. UK: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.4.6. Immunotherapy Drugs Market - France
    • 9.4.6.1. France: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.6.2. France: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.4.6.3. France: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.4.6.4. France: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.4.7. Immunotherapy Drugs Market - Germany
    • 9.4.7.1. Germany: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.7.2. Germany: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.4.7.3. Germany: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.4.7.4. Germany: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.4.8. Immunotherapy Drugs Market - Italy
    • 9.4.8.1. Italy: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.8.2. Italy: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.4.8.3. Italy: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.4.8.4. Italy: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.4.9. Immunotherapy Drugs Market - Spain
    • 9.4.9.1. Spain: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.9.2. Spain: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.4.9.3. Spain: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.4.9.4. Spain: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.4.10. Immunotherapy Drugs Market - Netherlands
    • 9.4.10.1. Netherlands: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.10.2. Netherlands: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.4.10.3. Netherlands: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.4.10.4. Netherlands: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.4.11. Immunotherapy Drugs Market - Russia
    • 9.4.11.1. Russia: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.11.2. Russia: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.4.11.3. Russia: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.4.11.4. Russia: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.4.12. Immunotherapy Drugs Market - Rest of Europe
    • 9.4.12.1. Rest of Europe: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.12.2. Rest of Europe: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.4.12.3. Rest of Europe: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.4.12.4. Rest of Europe: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
• 9.5. Immunotherapy Drugs Market - Asia Pacific
  • 9.5.1. Asia Pacific: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
  • 9.5.2. Asia Pacific: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • 9.5.3. Asia Pacific: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
  • 9.5.4. Asia Pacific: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.5.5. Immunotherapy Drugs Market - China
    • 9.5.5.1. China: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.5.2. China: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.5.5.3. China: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.5.5.4. China: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.5.6. Immunotherapy Drugs Market - India
    • 9.5.6.1. India: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.6.2. India: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.5.6.3. India: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.5.6.4. India: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.5.7. Immunotherapy Drugs Market - Malaysia
    • 9.5.7.1. Malaysia: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.7.2. Malaysia: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.5.7.3. Malaysia: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.5.7.4. Malaysia: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.5.8. Immunotherapy Drugs Market - Japan
    • 9.5.8.1. Japan: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.8.2. Japan: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.5.8.3. Japan: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.5.8.4. Japan: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.5.9. Immunotherapy Drugs Market - Indonesia
    • 9.5.9.1. Indonesia: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.9.2. Indonesia: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.5.9.3. Indonesia: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.5.9.4. Indonesia: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.5.10. Immunotherapy Drugs Market - South Korea
    • 9.5.10.1. South Korea: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.10.2. South Korea: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.5.10.3. South Korea: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.5.10.4. South Korea: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.5.11. Immunotherapy Drugs Market - Australia
    • 9.5.11.1. Australia: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.11.2. Australia: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.5.11.3. Australia: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.5.11.4. Australia: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.5.12. Immunotherapy Drugs Market - Rest of Asia Pacific
    • 9.5.12.1. Rest of Asia Pacific: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.12.2. Rest of Asia Pacific: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.5.12.3. Rest of Asia Pacific: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.5.12.4. Rest of Asia Pacific: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
• 9.6. Immunotherapy Drugs Market - Middle East & Africa
  • 9.6.1. Middle East & Africa: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
  • 9.6.2. Middle East & Africa: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • 9.6.3. Middle East & Africa: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
  • 9.6.4. Middle East & Africa: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.6.5. Immunotherapy Drugs Market - Saudi Arabia
    • 9.6.5.1. Saudi Arabia: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.6.5.2. Saudi Arabia: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.6.5.3. Saudi Arabia: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.6.5.4. Saudi Arabia: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.6.6. Immunotherapy Drugs Market - UAE
    • 9.6.6.1. UAE: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.6.6.2. UAE: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.6.6.3. UAE: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.6.6.4. UAE: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.6.7. Immunotherapy Drugs Market - Israel
    • 9.6.7.1. Israel: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.6.7.2. Israel: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.6.7.3. Israel: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.6.7.4. Israel: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.6.8. Immunotherapy Drugs Market - South Africa
    • 9.6.8.1. South Africa: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.6.8.2. South Africa: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.6.8.3. South Africa: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.6.8.4. South Africa: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.6.9. Immunotherapy Drugs Market - Rest of Middle East & Africa
    • 9.6.9.1. Rest of Middle East & Africa: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.6.9.2. Rest of Middle East & Africa: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.6.9.3. Rest of Middle East & Africa: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.6.9.4. Rest of Middle East & Africa: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
• 9.7. Immunotherapy Drugs Market - Latin America
  • 9.7.1. Latin America: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
  • 9.7.2. Latin America: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • 9.7.3. Latin America: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
  • 9.7.4. Latin America: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.7.5. Immunotherapy Drugs Market - Mexico
    • 9.7.5.1. Mexico: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.7.5.2. Mexico: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.7.5.3. Mexico: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.7.5.4. Mexico: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.7.6. Immunotherapy Drugs Market - Brazil
    • 9.7.6.1. Brazil: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.7.6.2. Brazil: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.7.6.3. Brazil: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.7.6.4. Brazil: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.7.7. Immunotherapy Drugs Market - Argentina
    • 9.7.7.1. Argentina: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.7.7.2. Argentina: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.7.7.3. Argentina: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.7.7.4. Argentina: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
  • 9.7.8. Immunotherapy Drugs Market - Rest of Latin America
    • 9.7.8.1. Rest of Latin America: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.7.8.2. Rest of Latin America: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.7.8.3. Rest of Latin America: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
    • 9.7.8.4. Rest of Latin America: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)

10. Competitive Landscape

• 10.1. Expansion and Acquisition Analysis
  • 10.1.1. Expansion
  • 10.1.2. Acquisitions
• 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

• 11.1. Abbvie Inc.
  • 11.1.1. Company Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Benchmarking
  • 11.1.4. Recent Development
• 11.2. Amgen Inc.
  • 11.2.1. Company Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Benchmarking
  • 11.2.4. Recent Development
• 11.3. AstraZeneca
  • 11.3.1. Company Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Benchmarking
  • 11.3.4. Recent Development
• 11.4. Bristol-Myers Squibb Company
  • 11.4.1. Company Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Benchmarking
  • 11.4.4. Recent Development
• 11.5. F. Hoffman-La Roche Ltd.
  • 11.5.1. Company Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Benchmarking
  • 11.5.4. Recent Development
• 11.6. Gilead Sciences, Inc.
  • 11.6.1. Company Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Benchmarking
  • 11.6.4. Recent Development
• 11.7. GSK PLC
  • 11.7.1. Company Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Benchmarking
  • 11.7.4. Recent Development
• 11.8. Johnson & Johnson Services, Inc.
  • 11.8.1. Company Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Benchmarking
  • 11.8.4. Recent Development
• 11.9. Merck & Co., Inc.
  • 11.9.1. Company Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Benchmarking
  • 11.9.4. Recent Development
• 11.10. Novartis AG
  • 11.10.1. Company Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Benchmarking
  • 11.10.4. Recent Development
• 11.11. Pfizer Inc.
  • 11.11.1. Company Overview
  • 11.11.2. Financial Performance
  • 11.11.3. Product Benchmarking
  • 11.11.4. Recent Development
• 11.12. Sanofi
  • 11.12.1. Company Overview
  • 11.12.2. Financial Performance
  • 11.12.3. Product Benchmarking
  • 11.12.4. Recent Development
• 11.13. Takeda Pharmaceutical Company Limited.
  • 11.13.1. Company Overview
  • 11.13.2. Financial Performance
  • 11.13.3. Product Benchmarking
  • 11.13.4. Recent Development
• 11.14. Teva Pharmaceutical Industries Ltd.
  • 11.14.1. Company Overview
  • 11.14.2. Financial Performance
  • 11.14.3. Product Benchmarking
  • 11.14.4. Recent Development